Background/Aim. Hormone D (vitamin D) plays an important role in immunoregulation and musculoskeletal metabolism.
Introduction
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease, affecting 0,5-1% of the population 1 .
The most prominent feature of the disease is synovitis of diarthrotic joints resulting in severe joint pain, reduced muscle strength and impaired physical function 2, 3 . Autoimmune driven synovium and systemic inflammation lead to cytokine dysregulation, elevation (3-100 times) of inflammatory cytokines in both beds [interleukin (IL) 6, interleukin 1 (IL1), tumor necrosis factor alpha (TNFα), etc], even during inactive phases of the disease [4] [5] [6] . Active RA also results in downregulation of sex steroids, growth hormone, anabolic factors such as insulin-like growth factor1 (IGF-1), insulin resistance and impairment of lipids metabolism, resulting in deleterious co-morbidities of the disease such as advanced atherosclerosis, muscle wasting-rheumatoid cachexia, osteoporosis [4] [5] [6] [7] . Rheumatoid cachexia is reported in two-thirds of all RA patients, as cytokine imbalance, hypermetabolism and inactivity driven accelerated loss of skeletal muscle mass with the elevation of fat mass contribute to functional disability and lowering of the quality of life 6 . The course of RA is typically one of exacerbations and remissions. Aggressive treatment of RA also treats co-morbidities 8 . All RA patients at some point of the disease course require adaptation of disease-modifying antirheumatic drug (DMARD) or corticosteroid (CS) therapy, and combined strength and endurance training. Despite anti-inflammatory, symptomatic and structural efficacy in RA, a CS use is suggested to be as short as possible, due to its adverse effects 8, 9 . The discovery of the immunomodulatory and antitumor properties of D hormone prompted researchers to investigate the possibility of its use as a therapeutic agent for autoimmune and malignant diseases [10] [11] [12] [13] [14] [15] [16] [17] [18] . During the last several decades, there were many investigations with the aim to synthesize hormone (vitamin) D analogs [vitamin D receptor (VDR) agonists] with the same biologic activity and even stronger anti-inflammatory properties, but with lower blood calcium-increasing capacity 13, 18 . One of steroidal VDR agonists, alfacalcidol (1αD3) differs from hormone D only by lacking the 25(OH) group. Agonists with the OH group in 1α position having the highest specificity of binding to VDR were developed based on the knowledge about the specificity of biochemical mechanisms of VDR binding with natural D hormone or its analogs 16 . There are numerous preclinical and clinical data on preventive and therapeutic potential of alfacalcidol in the primary and secondary osteoporosis, osteoporotic fractures, neuromuscular functioning, transplantation, displaying its exclusive pleiotropic capacity 11, 14, [19] [20] [21] [22] [23] [24] [25] [26] . Recently, greater intake of vitamin D is associated with a lower risk of RA, as well as the lower serum levels of vitamin D with higher disease activity 27, 28 . Hormone D deficiency in tissues, which is present in chronic inflammation, caused by inhibition of α-hydroxylase, can be corrected by alfacalcidol use, due to its activation in the liver or other target organs, bypassing body`s own feedback regulation 29, 30 . It has shown beneficial effects in autoimmune diseases such as RA and Psoriatic arthritis 11, 19 . Positive effect of alfacalcidol on regulating the cytokine homeostasis and increasing suppressor cells has been recognized 11, 19, 31, 32 . Recently, it has been shown that despite previous beliefs, it acts directly on inflammatory cytokine production without being additionally hydroxylated at the 25 position 33 . Due to the multifaceted potential of alfacalcidol in the autoimmune diseases, we wanted to assess its performance on joints and muscular features in clinical setting of active RA, at the point of current therapy adaptation. The aim of this study was to assess the impact of alfacalcidol or prednisone use on the muscle function and disease activity in active RA. The study population consisted of 67 active RA patients (46 females) on stable prior methotrexate (MTX) (10-25 mg/weekly) therapy and no steroids use for more than 3 months before enrollment. Patients were randomly assigned to administration of 1 μgr/daily 1αD3 (group A1, n = 17), 2 µg/daily 1αD3 (group A2, n = 19), 3 µg/daily 1αD3 (group A3, n = 16) treatment for 3 months or 20 mg of prednisone/daily for 1 month, followed by 10 mg prednisone/daily for 2 months (group C, n = 15), added to background stable MTX treatment. Alfacalcidol was provided by the investigator as gelatin capsules for oral administration (Alpha D3 R , TEVA, Serbia). Alfacalcidol dosing was modified only in case of toxicity, i.e. disturbances in calcium levels in blood or urine [more than 2.65 mmol/L in blood or more than 0.3 g daily in urine (DU) measured in two consecutive samples], drug dose half lowered during 1 week, until calcium and phosphorus levels normalized, then supplementation was re-started with the assigned treatment dose, if not, a patient was excluded from the study.
Methods

Study population and protocol
This
RA diagnosis was established at least 6 months prior the study started, using American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 criteria 34, 35 , and patients were eligible for participation if ESR-DAS28 was > 3.2 36 . Neither previous history of calcium metabolism disturbances or renal or bladder stones, nor any of following was allowed: psychiatric illness and/or social situation that would limit compliance with study medication and protocol requirements, signs and symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurologic or cerebral disease, inherited metabolic disease, pregnancy or lactation, presence of malignancy, or history of any malignancy in previous 10 years. Drugs which effect could be influenced or known to influence calcium or phosphorus metabolism, were not allowed. Any of the nonsteroidal antiinflammatory drugs (NSAIDs), the additional DMARDs or steroid drugs, not present at the enrollment, could not be used during the study. Patients were advised to maintain a daily fluid intake of at least 1.5 L throughout the duration of the study and to intake only dietary calcium.
Study outcomes and safety parameters
Demographic and clinical data were collected, blood samples were taken, muscle function tests and disease activity were assessed at the study entry and after 3 months after the treatment was assigned per protocol. Disease activity was assessed by the ESR DAS 28, calculated from the erythrocyte sedimentation rate (ESR), number of tender (TJC) and swollen joints (SJC) and the patients` assessment of disease activity (Patient Visual Analogue Scale -PVAS) based on the answer to the question "Given the overall impact of your arthritis to you, how are you feeling today?" Rated on a scale of 100 mm, answer may vary from 0 mmvery good to 100 mm -very poor, i.e. lower score reflected better state 37 . Muscle function was assessed by a battery of 4 tests usually used in the clinical setting:1) chair rising test (CRT), time to rise five times from a standard chair i.e. 46 cm high, with arms folded, shorter time (seconds) represent better muscle power 38 , 2) timed up and go (TUG) test, time taken to rise from a chair, walk 3 meters, turn around, walk back and sit down, shorter time (seconds) represent better muscle coordination 39, 40 , 3) 6-minutes walk test (6MWT) average distance (meters) of two attempts to walk during six minutes, longer distance represent better functional mobility 41 , and 4) tandem walk (TW), time (seconds) of walking heel-to-toe in a 2 meters straight line, shorter time represent better muscle balance 40 . Safety follow-up visits monitoring calcium metabolism were performed 2 weeks apart from the start and then they were followed monthly for the clinical and laboratory findings, as well as adverse events (AE). At each of two followup visits, the patients were assessed for any relevant change in the clinical status, weight, arterial pressure, electrocardiogram, ESR (Westergren method), routine hematology (Coulter HmX haematology analyzer), biochemistry such as Creactive protein (turbidimetry Gilford), glucose, albumin, liver enzymes, creatinine, uric acid, alkaline phosphatase, serum calcium, ionized calcium and 24 h calciuria were tested, while serum 25(OH)D3, (ECL electrochemiluminiscenceElecsys 2010) and parathormone (PTH) (FPIA-fluorescent polarisation imunoassay-AxSym Abbot) were determined only at the start and at the end of the treatment period.
Statistical analysis
Statistical analysis was performed using the SPSS 20 package [data are presented as mean±SD (min-max)]. Subgroup changes of variables pre and post treatment were analyzed by paired t-test or Wilcoxon's test. The subgroup differences were assessed by independent t-test, ANOVA or χ 2 test, as appropriate and least significant difference (LSD) method, post hoc; p < 0.05 was considered statistically significant in all analyses.
Results
Demographic and clinical characteristics of patient population
All patients completed 3 months study period. 
Influence on muscle function
Assessment of muscle function revealed improvement in the time needed to perform CRT in all therapeutic regimens, while in one group treated with 3 µg of 1αD3, the improvement was highly statistically significant (12.28 ± 3,464 vs 8.9 ± 2.33, p < 0.01, paired t-test) (Figure 1a) . Walking distance during 6 minutes (MWT) improved significantly in all treatment groups, in the A1 (437. 29 Figure 1b . Timed up and go test (TUG), improved in 2 µg, 3 µg 1αD3 and prednisone treated patients, yet only in the A2 group the difference pre-post treatment was statistically significant (7.67 ± 2.91 vs 6.02 ± 1.15, p < 0.05, paired t-test) (Figure 1c) . Tandem walk test (TW) slightly improved in all treatment groups, except in the A1 one, yet neither change was statistically significant. Subgroup analysis showed no difference in muscle tests changes pre-post treatment, except for ΔTUG (A2 vs C, p < 0.05, ANO-VA).
Influence on disease activity
Clinical efficacy indices showed marked improvement in term of ESR DAS28 in all therapeutic regimens, with highly statistically significant reduction achieved in the group A1 (5. treatment regimens in term of the disease activity, we used EULAR DAS28 response model 37 . Changes of the disease activity (ΔDAS28) during 12 week study in four different treatment regimens were A1 vs A2 vs A3 vs C, p < 0.05, ANOVA, while there was no difference in A2, the A3 groups vs C group (p = 0.437, post-hoc Fisher's Least Significant Difference -LSD), (Figure 1d ). Also, there was no significant difference in the number of patients with the good DAS28 EULAR response, which means the reduction of DAS28 > 1.2, in the groups A2, A3 and C (p = 0.532, χ2).
Influence on calcium metabolism parameters and safety issues
The patients reported overall good tolerability of study treatments, no serious adverse events or any laboratory or clinical adverse events were observed.
Compared to baseline levels, the serum 25(OH)D3 levels raised in all alfacalcidol treated patients, at the end of the study, while in patients treated with prednisone significantly decreased (34.02 ± 15.74 vs 21.93 ± 10.90, p < 0.01, paired t-test). PTH levels significantly decreased in the A2 group (31.2 ± 9.39 vs 26.42 ± 10.29, p < 0.05, paired ttest) and the A3 group (42.88 ± 11.66 vs 26.45 ± 13.401, p < 0,01, paired t-test) at the end of the treatment period.
The serum calcium and ionized calcium follow-up were particularly of interest, both remained unchanged in all treatment groups, while calciuria was significantly raised in the groups treated with alfacalcidol 2 µg and 3 µg, only in the latter group, the upper limit of normal exceeded slightly (ULN) of 0.3 g/DU (in the A2 0.18 ± 0.077 vs 0.27 ± 0.09, p < 0.01, in the A3 group 0.13 ± 0.047 vs 0.32 ± 0.11, p < 0.01, paired t-test). Alfacalcidol daily dose was corrected from 3 µg to 1 µg daily for 1 week in 4 patients, due to an increase in calciuria registered in 2 patients in the A3 group, 2 weeks, and 8 weeks apart from the start of the study, respectively. After daily dose reduction, calciuria normalized, and study treatment was continued as before.
The serum glucose levels raised pre-post treatment in the C group by 1.7 mmol/L (about 40% compared to baseline), yet not above ULN, in contrast to 1αD3 treated patients, who had about 2% lower glucose levels.
Discussion
As RA is associated with the significant physical disability, which has a negative impact on employment and health related quality of life. A primary goal for many patients is to maintain and improve physical function 42 . In the mutifactorial model of disability, skeletal muscle wasting and weakness in RA patients have a large influence 2, 3, 6 . Data on the impact of RA therapy on the skeletal muscle function are lacking. Contemporary aggressive sDMARD and bDMARD RA treatment, accompanied with exercises is effective, as for other metabolic co-morbidities, yet the challenge is to identify and treat any modifiable factors that contribute to physical disability 8, 36, 43 . Vitamin D3 (hormone D) deficiency may be one of it 20, 25 .
Evidence from recent meta-analysis of 16 randomized controlled trials (RCTs) of vitamin D treatment influence on muscle function, do support the beneficial effect of vitamin D supplementation on muscle strength and function in the elderly, vitamin D insufficient subjects, with major lack of data on the possible effect in younger people 43 . Identified studies were heterogeneous with regard to most aspects including the indices measured. Yet, some analogy can be made with the study of Lips et al. 44 who used a battery of physical performance tests including TUG, CRT, 6MWT, in 226 ambulatory patients, in which 8400 IU vitamin D3/weekly or placebo were applied for 4 months. They observed a rise in baseline vitamin D3 serum levels, yet no significant positive effect on muscle function was observed, compared to placebo. The average age of their study population was 78 years, with no data about co-morbidities. We had much younger (56 years), ill (RA) and vitamin D replete population (31.56 ng/mL) in our study. We observed better muscle functioning in all of our patients, except for TUG test in the 1 µg αD 3 subgroup (0.57 s), with the significant improvement in CRT, 6MWT (in 3 µg αD3 treated patients) and 6MWT and TUG (in 2 µg αD3 treated ones), accompanied with statistically significant serum 25(OH)D3 elevation and decrease of PTH in the same subgroups and highly statistically significant reduction of RA activity, also. Alfacalcidol 1 µg treated ones had significant reduction of disease activity (ΔDAS28 -0.84) accompanied with improvement in walking distance as measured by 6MWT, similar to findings of some improvement in muscle function noticed in prednisone treated ones, yet, only walking distance in 6MWT significantly increased, even they decreased the disease activity the most (ΔDAS28 -1.73). Our data additionally support the evidence of 1αD3 efficacy in RA, as we got highly significant improvement of the disease activity assessed by DAS28, in all alfacalcidol treated patients, as one of the most cited open labeled trial of alfacalcidol 2 µg use for twelve weeks in the active RA patients (n = 19), that showed significantly fewer swollen joints and improvement in two symptom scale scores, the Ritchie articular and Lee indices, with in vitro immunomodulatory effects on their lymphocytes 11 . Scharla et al. 26 showed that 1 µg alfacalcidol use for 3 months in RA vitamin D replete patients resulted in increase of lower extremity muscle power by isometric knee extension measurement (60%) compared to native vitamin D 1000 IU use (18%). We also observed an increase in CRT as a measure of muscle power in all alfacalcidol treated patients. It is of importance that no endurance nor strength training in any of our subjects was applied.
Study of muscle biopsies in osteoporotic patients showed that 1 µg alfacalcidol treatment for 3-6 months, induced an increase in the relative number and cross-sectional area of fast-twitch type IIA muscle fibers, accompanied by the reduction of fast-switch type IIB fibers, altogether with the improvement in activities of daily living 45 . We did not perform any imaging or morphological analysis of muscle tissue, while the clinical impression of the reduced disease activity index and increased mobility in our patients was im- pressive. This represents the starting point for future investigations of 1αD 3 in RA patients in a placebo-controlled manner, including whole body densitometry scan with an estimation of lean/fat mass pre-post treatment.
We can say that the most gain of three-month study treatment in active RA patients was observed when 2 µg and 3 µg 1αD3 were used, as a dual action on inflammation and muscle performance was documented. Dual effect of alfacalcidol treatment is observed in osteoporotic subjects, both in primary and corticosteroid induced osteoporosis 23, 24, [46] [47] [48] . Meta-analysis of those studies showed a reduction of fracture rates as the result of improved bone mass, quality and a reduction of falls by improvement of muscle function, which was the exclusive action of alfacalcidol 24, 48 . Hypercalcemia as the adverse effect is rare in alfacalcidol use, as shown in post-marketing surveillance of 13550 osteoporotic patients 49 . We used high doses of alfacalcidol, but also found no hypercalcemia, yet, reversible calciuria occurred in 2 µg and 3 µg treated subjects, not of clinical importance.
Prednisone treatment (average 13.3 mg daily, for 3 months) in our study resulted in a highly significant reduction of serum level of 25(OH)D3, which was definitely not a desirable state, as it was closely negatively related to at least RA disease activity 28, 50 . On the contrary, anti-inflammatory effects of all three alfacalcidol treatment regimens in our study resulted in increased levels of serum 25(OH)D3, lower serum PTH, the state which is known to be related to better muscle mass and strength, reduced falls rate, better physical performance as was shown in systematic review of Schacht and Richy 51 and in 3 year`s prospective study of Visser et al. 52 . All the benefits of the disease activity, PTH metabolism and muscle function of 1αD3 supplementation in active RA, did not result from correcting vitamin D deficiency since the patients were already vitamin D replete. We assume that direct effect of high doses of alfacalcidol on the nuclear VDRs in different target tissues produced such effects. Corticosteroids are widely used due to their symptomatic, antiinflammatory and structural effects in active RA 8, 9 .
Conclusion
Based on our findings, alfacalcidol might find its place as bridging therapy instead of corticosteroids, in at least selected group of RA patients. Three-month alfacalcidol treatment is as effective as prednisone in the disease control and has the dose dependent positive effect on muscle function in vitamin D replete active RA patients with a good safety profile.
